EUVIMEDEUVIMED entdecken
Crossref

Identifying lutetium-177 prostate-specific membrane antigen-617 treatment response patterns using a quantitative prostate-specific membrane antigen positron emission tomography/computed tomography traffic light workflow within the LuPIN trial

Sarennya Pathmanandavel, Megan Crumbaker, Andrew Nguyen, Andrew O. Yam, Peter Wilson, Remy Niman, Maria Ayers, Shikha Sharma, Peter Eu, Andrew J. Martin, Martin R. Stockler, Anthony M. Joshua und 1 weitere

Advances in Radiotherapy & Nuclear Medicine · 2025

DOI: 10.36922/arnm025110011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Radiotherapy & Nuclear Medicine, 2025. Verfasst von Sarennya Pathmanandavel und 12 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lutetium-177 prostate-specific membrane antigen-617 (177Lu-PSMA-617) improves survival in metastatic castration-resistant prostate cancer, but more optimal tools are needed for therapeutic response assessment and early detection of resistance. We evaluated a quantitative imaging workflow using prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography to measure lesional changes following 177Lu-PSMA-617 therapy. Pre- and post-treatment gallium-68-labeled PSMA-11 PET scans from the trial were analyzed using a novel traffic light workflow (TLW), assessing lesion-specific changes in tumor volume and maximum standardized uptake value in men treated with up to six cycles of 177Lu-PSMA-617 and a radiation sensitizer (NOX66). Lesions were categorized as “reducing” (≥30% volume decrease), “stable” (50% prostate-specific antigen (PSA) decline. The median PSA progression-free survival (PSA-PFS) was 8.6 months; median OS was 22.0 months. At post-treatment imaging, 54% (20/37) showed progression. TLW classified 24% as “responders,” 41% as “low-volume progressors,” and 35% as “high-volume progressors.” “Responders” had longer OS than “low-volume progressors” (median 17.7 vs. 12.0 months) or “high-volume progressors” (median 7.5 months, p=0.005). RECIP 1.0 classified 24% as partial response, 51% stable disease, and 24% as progressive disease. In summary, TLW shows potential to delineate complex response patterns. Following validation in larger cohorts, TLW will inform therapeutic decision-making.

Zitieren

APA

Pathmanandavel, S., Crumbaker, M., Nguyen, A., Yam, A. O., Wilson, P., Niman, R., Ayers, M., Sharma, S., Eu, P., Martin, A. J., Stockler, M. R., Joshua, A. M., & Emmett, L. (2025). Identifying lutetium-177 prostate-specific membrane antigen-617 treatment response patterns using a quantitative prostate-specific membrane antigen positron emission tomography/computed tomography traffic light workflow within the LuPIN trial. Advances in Radiotherapy & Nuclear Medicine. https://doi.org/10.36922/arnm025110011

Vancouver

Pathmanandavel S, Crumbaker M, Nguyen A, Yam AO, Wilson P, Niman R, et al. Identifying lutetium-177 prostate-specific membrane antigen-617 treatment response patterns using a quantitative prostate-specific membrane antigen positron emission tomography/computed tomography traffic light workflow within the LuPIN trial. Advances in Radiotherapy & Nuclear Medicine. 2025. doi:10.36922/arnm025110011

BibTeX
@article{Pathmanandavel2025,
  author = {Pathmanandavel, Sarennya and Crumbaker, Megan and Nguyen, Andrew and Yam, Andrew O. and Wilson, Peter and Niman, Remy and Ayers, Maria and Sharma, Shikha and Eu, Peter and Martin, Andrew J. and Stockler, Martin R. and Joshua, Anthony M. and Emmett, Louise},
  title = {Identifying lutetium-177 prostate-specific membrane antigen-617 treatment response patterns using a quantitative prostate-specific membrane antigen positron emission tomography/computed tomography traffic light workflow within the LuPIN trial},
  journal = {Advances in Radiotherapy & Nuclear Medicine},
  year = {2025},
  doi = {10.36922/arnm025110011}
}
Kostenlos starten →